NASDAQ: LYRA - Lyra Therapeutics, Inc.

半年間の収益性: -40.58%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Lyra Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

さらに詳しく
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://lyratherapeutics.com
Цена ао 0.1559
1日あたりの価格変動: 0% (0.1527)
週ごとの価格変動: -12.74% (0.175)
月ごとの料金変更: -25.58% (0.2052)
3ヶ月間の価格変動: -19.84% (0.1905)
半年間の価格変動: -40.58% (0.257)
年間の価格変動: -97.55% (6.22)
3年間の価格推移: -96.71% (4.645)
年初からの価格変動: -26.02% (0.2064)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 8.76 1
P/BV 1.16 9
P/E 0 0
EV/EBITDA -0.0752 0
合計: 5

効率

名前 意味 学年
ROA, % -89.43 0
ROE, % -184.99 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.3568 10
合計: 8.8

成長の衝動

名前 意味 学年
収益性 Revenue, % 27.83 4
収益性 Ebitda, % 335.96 10
収益性 EPS, % -44.17 0
合計: 6.8
さらに詳しく

機関 音量 共有, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.00348 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.04 0.6026
ProShares UltraPro Russell2000 0.0003 89.82 1.47873
ProShares Hedge Replication ETF 0.00008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
031.851.2



スーパーバイザー 役職 支払い 生年
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 年)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 年)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 年)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 年)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 年)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 年)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

住所: United States, Watertown. MA, 480 Arsenal Way - Googleマップで開く, Yandexマップを開く
Webサイト: https://lyratherapeutics.com